Teva and Mylan: War of words continues
This article was originally published in Scrip
Teva and Mylan continue to exchange strongly worded correspondence. On 8 June, Teva's chairman Yitzhak Peterburg and CEO Erez Vigodman issued an open letter to Mylan's executive chairman Robert Coury repeating Teva's $40bn offer for the company and claiming that a combination would add value to both companies. However, they also claimed that Mylan's management was making "grossly incorrect" statements to mislead its stockholders and deprive them of a transparent analysis of Teva's proposal.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.